Publications

Homer JJ, Winter SC, Abbey EC, Aga H, Agrawal R, Ap Dafydd D, Arunjit T, Axon P, Aynsley E, Bagwan IN, Batra A, Begg D, Bernstein JM, Betts G, Bicknell C, Bisase B, Brady GC, Brennan P, Brunet A, Bryant V, Cantwell L, Chandra A, Chengot P, Chua ML, et al. Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition. J Laryngol Otol 2024; 138(S1): S1-S224. (IF 1.1) https://doi.org/10.1017/S0022215123001615

Pan JJ, Mai HQ, Ng WT, Hu CS, Li JG, Chen XZ, Chow JCH, Wong E, Lee V, Ma LY, Guo QJ, Liu Q, Liu LZ, Xu TT, Gong XC, Qiang MY, Au KH, Liu TC, Chiang CL, Xiao YP, Lin SJ, Chen YB, Guo SS, Wong CHL, Tang LQ, Xu ZY, Jia YZ, Peng WS, Hu LP, Lu TZ, Jiang F, Cao CN, Xu W, Ma J, Blanchard P, Williams M, Glastonbury CM, King AD, Patel SG, Seethala RR, Colevas AD, Fan DM, Chua ML (Co-Senior), et al. Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. JAMA Oncol 2024. (IF 22.5) https://doi.org/10.1001/jamaoncol.2024.4354 

Haas R, Frame G, Khan S, Neilsen BK, Hong BH, Yeo CPX, Yamaguchi TN, Ong EHW, Zhao W, Carlin B, Yeo ELL, Tan KM, Bugh YZ, Zhu C, Hugh-White R, Livingstone J, Poon DJJ, Chu PL, Patel Y, Tao S, Ignatchenko V, Kurganovs NJ, Higgins GS, Downes MR, Loblaw A, Vesprini D, Kishan AU, Chua ML, et al. The Proteogenomics of Prostate Cancer Radioresistance. Cancer Res Commun. 2024. (IF 2.0)  https://doi.org/10.1158/2767-9764.CRC-24-0292

Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, et al. Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database. Eur J Cancer 2024. (IF 8.4) https://doi.org/10.1016/j.ejca.2024.114038

Li JS, Blanchard P, Wong CHL, Ahn YC, Bonomo P, Bresson D, Caudell J, Chen MY, Chow VLY, Chua ML, et al. International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2024. https://doi.org/10.1016/j.ijrobp.2024.07.2143

Tan HQ, Cai JH, Tay SH, Sim AY, Huang L, Chua ML (Co-Senior), et al. Cluster-Based Radiomics Reveal Spatial Heterogeneity of Bevacizumab Response for Treatment of Radiotherapy-induced Cerebral Necrosis. Comput Struct Biotechnol J 2023; 23: 43-51. (IF 7.7) https://doi.org/10.1016/j.csbj.2023.11.040

Wang X, Huang N, Yip PL, Wang J, Huang R, Sun Z, Kang D, He Q, Deng X, Zhao C, Chua ML, Han F. The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-world study with a large population. Radiother Oncol. 2024 May;194:110154. https://doi.org/10.1016/j.radonc.2024.110154

Chiong E, Murphy DG, Buchan N, Chen K, Chen SS, Chua ML, et al; ANZUP Cancer Trials Group; Davis ID. Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023. Asia Pac J Clin Oncol 2024. (IF 1.9) https://doi.org/10.1111/ajco.14064

Zhang X, Yan J, Lei Q, Neo J, Tan SH, Shu X, Huang L, Long B, Xie Y, Wang F, Wang Y, Tu H, Wang C, Zhang L, Yang J, Zhang J, Liu H, Lim DWT, Chua ML, et al. Randomized, Multicenter, Phase 2 Trial of Camrelizumab With or Without Metastasis-directed Stereotactic Body Radiation Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2025 Mar 15;121(4):980-990. https://doi.org/10.1016/j.ijrobp.2024.10.019

Yip PL, You R, Chen MY, Chua ML. Embracing Personalized Strategies in Radiotherapy for Nasopharyngeal Carcinoma: Beyond the Conventional Bounds of Fields and Borders. Cancers 2024; 16(2): 383. (IF 5.2) https://doi.org/10.3390/cancers16020383

Tan JS, Tay TK, Ong EH, Fehlings M, Tan DS, Sukma NB, Chen EX, Sng JH, Yip CSP, Lim KH, Lim DW, Iyer NG, Hwang JS, Chua ML (Co-Senior), et al. Combinatorial Hypofractionated Radiotherapy and Pembrolizumab in Anaplastic Thyroid Cancer. Eur Thyroid J 2024: ETJ-23-0144. (IF 4.7) https://doi.org/10.1530/ETJ-23-0144 

Zhu HC, Chua ML, et al. Global radiotherapy demands and corresponding medical professional workforce requirements: Current status and projected needs of 2050. Lancet Glob Health 2024: S2214-109X(24)00355-3. (IF 34.3) https://doi.org/10.1016/S2214-109X(24)00355-3 

Ang D, Chan J, Ong WS, Tan HS, Ng QS, Yuen J, Chen K, Tay KJ, Wong SW, Saad M, Nagata M, Horie S, Chansriwong P, Ng CF, Wong A, Chua ML, et al. Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2024; 8: e2300694. (IF 4.6) https://doi.org/10.1200/PO.23.00694 

Chiong E, Saad M, Hamid ARAH, Ong-Cornel AB, Lojanapiwat B, Pripatnanont C, Serrano D, Songco J, Sin LC, Hakim L, Chua ML, et al. Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns. Ther Adv Med Oncol 2024; 16: 17588359231216582. (IF 4.9) https://doi.org/10.1177/17588359231216582 

Tay SB, Low GH, Wong GJE, Tey HJ, Leong FL, Li C, Chua ML, et al. Use of Natural Language Processing to Infer Sites of Metastatic Disease From Radiology Reports at Scale. JCO Clin Cancer Inform 2024; 8: e2300122. (IF 4.2) https://doi.org/10.1200/CCI.23.00122

Zhuang Q, Zhang AY, Cong RSTY, Yang GM, Neo PSH, Tan DS, Chua ML, et al. Towards proactive palliative care in oncology: developing an explainable EHR-based machine learning model for mortality risk prediction. BMC Palliat Care 2024; 23(1): 124. (IF 3.1) https://doi.org/10.1186/s12904-024-01457-9 

Gatsinga R, Tan YG, Chen W, Yang X, Tuan JKL, Chua ML, et al. Lost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings. Transl Androl Urol 2024; 13(9): 1786-94. (IF 1.9) https://doi.org/10.21037/tau-24-130

Velaga J, Tay KJ, Hang GQ, Tan YG, Yuen JS, Chua ML, et al. Surveillance one year post focal cryotherapy for clinically significant prostate cancer using mpMRI and PIRADS v2.1: An initial experience from a prospective phase II mandatory biopsy study. Eur J Radiol Open 2023; 11: 100529. (IF 2.0) https://doi.org/10.1016/j.ejro.2024.100556 

Neo J, Yip PL, Ong EHW, Miao J, Chow WM, Wee JTS, Fong KW, Soong YL, Tan TWK, Tan JSH, Sin SY, Liu J, Loh KS, Tay JK, Ang MK, Tan SH, Lim DWT, Chua ML. Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma. Oral Oncol. 2024 Jan;148:106655. https://doi.org/10.1016/j.oraloncology.2023.106655

Beh CY, Yeo CPX, Hong BH, Tan EMC, Tan KM, Poon DJJ, Chu PL, Susanti D, Tai PL, Ryu M, Proudfoot J, Yeo ELL, Soo KC, Chua ML. Genomic and transcriptomic profiling of radioresistant prostate and head and neck cancers implicate a BAHD1-dependent modification of DNA damage at the heterochromatin. Cell Death Dis 2024; 15(12): 929. (IF 8.1)  https://doi.org/10.1038/s41419-024-07316-y

Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Chua ML, et al. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol 2024. (IF 25.3) https://doi.org/10.1016/j.eururo.2024.09.005

Lim CY, Ng GWY, Goh CK, Chua ML, et al. Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression. Oral Oncol 2024; 157: 106941. (IF 4.0) https://doi.org/10.1016/j.oraloncology.2024.106941

Tan JS, Tay TK, Ong EH, Fehlings M, Tan DS, Sukma NB, Chen EX, Sng JH, Yip CS, Lim KH, Lim DW, Iyer NG, Hwang JS, Chua ML (Co-Senior), et al. Combinatorial Hypofractionated Radiotherapy (RT) and Pembrolizumab in Anaplastic Thyroid Cancer. Eur Thyroid J. 2024 Jan 1; 13(1) (IF 4.7) https://doi.org/10.1530/etj-23-0144

Chiong E, Saad M, Kanesvaran R, Umbas R, Rizal A, Ong-Cornel A, Lojanapiwat B, Pripatnanont C, Serrano D, Songco J, Loh CS, Hakim L, Chua ML, et al. Prostate Cancer Management in South-East Asian Countries: A Survey of Clinical Practice Patterns. Ther Adv Med Oncol. 2024 Jan 18;16. (IF 4.9) https://doi.org/10.1177/17588359231216582

Neo JL, Yip PL, Ong EH, Miao JJ, Chow WM, Wee JT, Fong KW, Soong YL, Tan TW, Tan JS, Sin SY, Liu JJ, Loh KS, Tay JK, Ang MK, Tan SH, Lim DW, Chua ML. Longitudinal Post-radiotherapy Plasma Epstein-Barr Virus DNA Trends Inform on Optimal Risk Stratification in Endemic Nasopharyngeal Carcinoma. Oral Oncol. 2023 Dec 5; 148: 106655. (IF 4.8) https://doi.org/10.1016/j.oraloncology.2023.106655

Tay SH, Zhang X, Chua ML. Radiomics in Precision Oncology: Hype or Ludum Mutante. BMC Med. 2023 Nov 28; 21(1): 465. (IF 9.3) https://doi.org/10.1186/s12916-023-03165-2

Tan HQ, Cai JH, Tay SH, Sim AY, Huang L, Chua ML (Co-Senior), et al. Cluster-Based Radiomics Reveal Spatial Heterogeneity of Bevacizumab Response for Treatment of Radiotherapy-induced Cerebral Necrosis. Comput Struct Biotechnol J. 2023 Nov 24; 23: 43-51. (IF.7.7) https://doi.org/10.1016/j.csbj.2023.11.040

Goh D, Lim KH, Sudirman SRB, Ang MK, Chua ML, et al. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report. Chin Clin Oncol. 2023 Oct 31; 12(5): 57. (IF 2.8) https://doi.org/10.21037/cco-23-55

Velaga J, Tay KJ, Hang GQ, Tan YG, Yuen JS, Chua ML, et al. Surveillance one year post focal cryotherapy for clinically significant prostate cancer using mpMRI and PIRADS v2.1: An initial experience from a prospective phase II mandatory biopsy study. Eur J Radiol Open. 2023 Oct 21; 11: 100529. (IF 2.0) https://doi.org/10.1016/j.ejro.2023.100529

Naderi E, Aguado-Barrera ME, Schack LMH,… Chua ML, Large-Scale Meta-GWAS Reveals Common Genetic Factors Linked to Radiation-Induced Acute Toxicities across Cancers. JNCI Cancer Spectr. 2023 Oct 20: pkad088. (IF 4.4) https://doi.org/10.1093/jncics/pkad088

Locati LD, Ferrarotto R, Licitra L, Benazzo M, Preda L, Farina D, Gatta G, Lombardi D, Nicolai P, Vander Poorten V, Chua ML, et al. Current management and future challenges in salivary glands cancer. Front Oncol. 2023 Sep 19; 13. (IF 4.7) https://doi.org/10.3389/fonc.2023.1264287

Zhang T, Wei Y, Hong BH, Sumiyoshi T, Ong EHW, Zeng H, Li Y, Ng CF, Pan J, Fang B, Wang B, Wu J, Wang H, Akamatsu S, Chua ML (Co-Senior), et al. Development and validation of a nomogram (APGRC) to predict the presence of germline DNA damage repair pathogenic variants in Asian patients with prostate cancer. Clin Transl Med. 2023 Sep 12; 13(9): e1411. (IF 10.6) https://doi.org/10.1002/ctm2.1411

Chua ML, et al. Transcriptomic Analyses of Localised Prostate Cancers of East Asian and North American Men Reveal Race-specific Luminal-Basal and Microenvironmental Differences. Cancer Commun (Lond). 2023 Sep 12; 43(10): 1164-8. (IF 16.2) https://doi.org/10.1002/cac2.12467

Tan RSYC, Lin Q, Low GH, Lin R, Goh TC, Chang CCE, Lee FF, Chan WY, Tan WC, Tey HJ, Leong FL, Tan HQ, Nei WL, Chay WY, Tai DWM, Lai GGY, Cheng LT, Wong FY, Chua MCH, Chua ML, et al. Inferring cancer disease response from radiology reports using large language models with data augmentation and prompting. J Am Med Inform Assoc. 2023 Jul 14; 30(10): 1657–1664. (IF 7.942) https://doi.org/10.1093/jamia/ocad133

Yang X, Tan YG, Gatsinga R, Chen W, Huang HH, Loong JTK, Chua ML, et al. Far from the truth: Realworld treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification. Int J Urol. 2023 Jul 11; 30(11): 991-999. (IF 2.896) https://doi.org/10.1111/iju.15243

Yip PL, Lee AW, Chua ML. Adjuvant Chemotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. Lancet Oncol. 2023 Jul: S1470-2045(23) 00266-8. (IF 54.433) https://doi.org/10.1016/s1470-2045(23)00266-8

Desai NB, Dal Pra A, Chua ML, et al. Passing the Kool-Aid Point: mRNA Expression-Based Risk Classifiers in Localized Prostate Cancer Treatment Decision Making. Int J Radiat Oncol Biol Phys. 2023 Jul 1; 116(3): 530- 2. (IF 8.013) https://doi.org/10.1016/j.ijrobp.2022.12.002

Viani GA, Gouveia AG, Matsuura FK, Neves LVF, Marta GN, Chua ML, et al. Assessing the efficacy of palliative radiation treatment schemes for locally advanced squamous cell carcinoma of the head and neck: a meta-analysis. Rep Pract Oncol Radiother. 2023 Jun 26; 28(2): 137-46. (IF 1.2) https://doi.org/10.5603/rpor.a2023.0021

Akimoto T, Aoyama H, Chua ML, et al. Challenges and Opportunities With the Use of Hypofractionated Radiation Therapy in Cancer Care: Regional Perspectives From South Korea, Japan, Singapore, and Australia. Adv Radiat Oncol. 2023 Jun 14; 8(6): 101291. (IF 4.5) https://doi.org/10.1016/j.adro.2023.101291

Poh SS, Tan BF, Yong FY, Fong KW, Wee JTS, Tan TWK, Chua ML, et al. The impact of the COVID-19 pandemic on nasopharyngeal carcinoma patients - a national cancer centre experience. Holist Integr Oncol. 2023 Jun 7; 2(1): 17. https://doi.org/10.1007/s44178-023-00041-0

Berlin A, Ramotar M, Santiago AT, Liu Z, Li J, Wolinsky H, Wallis CJD, Chua ML, et al. The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 Jun 7; 115(11): 1364-1373. (IF 11.816) https://doi.org/10.1093/jnci/djad108

Petit C, Lee A, Ma J, Lacas B, et al.; MAC-NPC Collaborative Group. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis. Lancet Oncol. 2023 Jun; 24(6): 611-23. (IF 54.433) https://doi.org/10.1016/s1470-2045(23)00163-8

Lim DW, Kao H-F, Suteja L, Li CH, Quah HS, Tan DS, Tan SH, Tan EH, Tan WL, Lee JN, Ting FW, Jain A, Goh BC, Chua ML, et al. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nat Commun. 2023 May 15; 14(1): 2781. (IF 17.69) https://doi.org/10.1038/s41467-023-38407-7

Weiner A, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JJ, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, Chua ML, et al. Machine learning of 100,000 genome-wide expression profiles identifies distinct prostate cancer luminal and basal phenotypes: implications for treatment stratification. Cancer. 2023 Apr 14; 129(14): 2169 – 2178. (IF 6.921) https://doi.org/10.1002/cncr.34790

Kanesvaran R, Chia PL, Chiong E, Chua ML, et al. An Approach to Genetic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Singapore. Ann Acad Med Singap. 2023 Mar 30; 52(3):135-148 (IF 8.713) https://doi.org/10.47102/annals-acadmedsg.2022372

 Chua ML, et al. Hyperfractionation for re-irradiation of recurrent nasopharyngeal carcinoma. Lancet. 2023 Mar 18; 401(10380): 878-9. (IF 202.7) https://doi.org/10.1016/s0140-6736(23)00389-6

Tan YG, Law YM, Ngo NT, Khor LY, Tan PH, Ong EH, Yuen JS, Ho HS, Tuan JK, Kanesvaran R, Gupta R, Rozen S, Chua ML, et al. Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A phase II mandatory biopsy-monitored study. Prostate. 2023 Mar 9; 83(8): 781-91. (IF 4.104) https://doi.org/10.1002/pros.24517

Miao JJ, Wang L, Ong EH, Hu CS, Lin SJ, Chen XZ, Chen YY, Zhong YH, Jin F, Lin Q, Lin SM, Hu XF, Zhang N, Wang RS, Wang C, Guo X, Yit NL, Shin HP, Tan SH, Mai HQ, Xie CH, Chua ML (Co-Senior), et al. Effects of Induction Chemotherapy on Nutrition Status in Locally-advanced Nasopharyngeal Carcinoma: A Multicenter Prospective Study. J Cachexia Sarcopenia Muscle. 2023 Mar 5; 14(2): 815-25. (IF 12.063) https://doi.org/10.1002/jcsm.13196

Chua ML, et al. Management of the neck in nasopharyngeal carcinoma-time for a radical change? Chin Clin Oncol. 2023 Feb 28; 12(1): 8. (IF 2.8) https://doi.org/10.21037/cco-22-95

Cheng J, Jiang J, He B, Lin WJ, Li Y, Duan J, Li H, Huang X, Cai J, Xie J, Zhang Z, Yang Y, Xu Y, Hu X, Wu M, Zhuo X, Liu Q, Shi Z, Yu P, Rong X, Ye X, Saw PE, Wu LJ, Simone CB 2nd, Chua ML, et al. A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury. Sci Transl Med. 2023 Feb 22; 15(684). (IF 19.319) https://doi.org/10.1126/scitranslmed.abm6543

de Guzman RB, Chua ML, et al. ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific. JCO Glob Oncol. 2023 Feb 22; 9(9). https://doi.org/10.1200/go.22.00313

Lam JW, King AD, Miller JA, Liu ZW, Yu KJ, Chua ML, et al. Recommendations for Epstein-Barr virusbased screening and management for the early detection of nasopharyngeal cancer in high- and intermediate-risk regions. J Natl Cancer Inst. 2023 Feb 1; 115(4): 355-64. (IF 11.816) https://doi.org/10.1093/jnci/djad012

Chia BSH, Ho SZ, Tan HQ, Chua ML, et al. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5; 15(2): 346. (IF 6.565) https://doi.org/10.3390/cancers15020346

Chua ML. Stochastic Stomatitis: Radiation Recall Reactions in the Era of Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):9. https://doi.org/10.1016/j.ijrobp.2022.07.024 

Park SH, Hong SH, Kim K, Lee SW, Yon DK, Jung SJ, Abdeen Z, Brahim Ahmed MLC, Serouri AA, Al-Herz W, Subbaram K, Shaik Syed P, Ali S, Ali K, Al-Shamsi HO, Baatarkhuu O, Nielsen HB, Bernini-Carri E, Bondarenko A, Cassell A, Cham A, Chua ML, et al. Non-Pharmaceutical Interventions Reduce the Incidence, and Mortality of COVID-19: A Study based on the Survey from the International COVID-19 Research Network (ICRN). J Med Virol. 2022 Nov 29. https://doi.org/10.1002/jmv.28354 

Yeo BS, Song HJ, Soong YL, Chua ML, et al. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis. Oral Oncol. 2022 Nov 19;136:106242. https://doi.org/10.1016/j.oraloncology.2022.106242 

Naderi E, Schack LM, Welsh C, Sim AY, Aguado-Barrera ME, Dudding T, Summersgil H, Martínez-Calvo L, Ong EH, Odding Y, Varela-Pazos A, Steenbakkers RJH, Crijns AP, Jena R, Pring M, Dennis J, Lobato-Busto R, Alsner J, Ness A, Nutting C, Thomson DJ, Gómez-Caamaño A, Eriksen JG, Thomas SJ, Bates AM, Overgaard J, Cascallar-Caneda LM, Duprez F, Barnett GC, Dorling L, Chua ML, et al; On the behalf of the Radiogenomics Consortium. Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer. Radiother Oncol. 2022 Nov;176:138-148. https://doi.org/10.1016/j.radonc.2022.09.016 

Miao J, Wang L, Tan SH, Li JG, Yi J, Ong EH, Tan LL, Zhang Y, Gong X, Chen Q, Xiang YQ, Chen MY, Guo Y, Lv X, Xia WX, Tang L, Deng X, Guo X, Han F, Mai HQ, Chua ML, Zhao C. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2022 Oct 13:e224656. https://doi.org/10.1001/jamaoncol.2022.4656 

Murgić J, Fröbe A, Chua ML. Recent Advances in Radiotherapy Modalities for Prostate Cancer. Acta Clin Croat. 2022 Oct;61(Suppl 3):57-64. https://doi.org/10.20471/acc.2022.61.s3.8 

Yang X, Allen JC, Aslim EJ, Tay KJ, Yuen SPJ, Kanesvaran R, Chua ML, et al. Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial. Int J Urol. 2022 Aug 24. https://doi.org/10.1111/iju.14994 

Ng WT, But B, Wong CH, Choi CW, Chua ML, Blanchard P, Lee AW. Particle beam therapy for nasopharyngeal cancer: A systematic review and meta-analysis. Clin Transl Radiat Oncol. 2022 Aug 23;37:41-56. https://doi.org/10.1111/iju.14994 

Eala MA, Dee EC, Ginsburg O, Chua ML, Bhoo-Pathy N. Financial toxicities of cancer in low- and middle-income countries: Perspectives from Southeast Asia. Cancer. 2022 Aug 15;128(16):3013-3015. https://doi.org/10.1002/cncr.34353 

Pan D, Rong X, Chen D, Jiang J, Ng WT, Mai H, Li Y, Li H, Cai J, Cheng J, Xu Y, Chua ML, et al. Mortality of early treatment for radiation-induced brain necrosis in head and neck cancer survivors: A multicentre, retrospective, registry-based cohort study. EClinicalMedicine. 2022 Aug 12;52:101618. https://doi.org/10.1016/j.eclinm.2022.101618 

Kanesvaran R, Castro E, Wong A, Fizazi K, Chua ML, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open. 2022 Aug;7(4):100518. https://doi.org/10.3390/cancers14153680 

Lee NY, Hum M, Ong PY, Myint MK, Ong EH, Low KP, Li Z, Goh BC, Tay JK, Loh KS, Chua ML, et al. Germline Variants Associated with Nasopharyngeal Carcinoma Predisposition Identified through Whole-Exome Sequencing. Cancers (Basel). 2022 Jul 28;14(15):3680. https://doi.org/10.1016/j.esmoop.2022.100518 

Dee EC, Eala MAB, Chua ML, Bray F, Bhoo-Pathy N. Adolescents and young adults with cancer: Considerations from the Southeast Asian perspective. Pediatr Blood Cancer. 2022 Jul;69(7):e29593. https://doi.org/10.1002/pbc.29593 

Brastianos HC, Murgic J, Salcedo A, Chua ML, et al. Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. Eur Urol Oncol. 2022 Jun;5(3):362-365. https://doi.org/10.1016/j.euo.2020.06.005

McDowell L, Chua ML, et al. A Bit More Here and a Little Less There: The Trials (and Tribulations) of Adjuvant and Neoadjuvant Head and Neck Studies in 2021. Int J Radiat Oncol Biol Phys. 2022 Jun 1;113(2):243-251. https://doi.org/10.1016/j.ijrobp.2022.02.016

He L, Pi Y, Li Y, Wu Y, Jiang J, Rong X, Cai J, Yue Z, Cheng J, Li H, Chua ML, et al; written on behalf of Radiation Oncology Palliative Care Collaborative Group. Efficacy and safety of apatinib in radiation-induced brain injury among head and neck cancer: an open-label, single-arm, phase 2 study. Int J Radiat Oncol Biol Phys. 2022 Apr 1:S0360-3016(22)00268-1. https://doi.org/10.1016/j.ijrobp.2022.03.027 

Teng YHF, Quah HS, Suteja L, Dias JML, Mupo A, Bashford-Rogers RJM, Vassiliou GS, Chua ML, Tan DSW, Lim DWT, Iyer NG. Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. Cancer Immunol Immunother. 2022 Apr;71(4):989-998. https://doi.org/10.1007/s00262-021-03047-7 

Ng WT, Chua ML, Lee AWM. Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box? JAMA Oncol. 2022 Apr 1;8(4):524-525. https://doi.org/10.1001/jamaoncol.2021.7365

Schack LM, Naderi E, Fachal L, Dorling L, Luccarini C, Dunning AM; Head and Neck Group of the Radiogenomics Consortium; Danish Head and Neck Cancer Group (DAHANCA), Ong EH, Chua ML, et al. A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. Br J Cancer. 2022 Apr;126(7):1082-1090. https://doi.org/10.1038/s41416-021-01670-w 

Li Y, Ong WS, Shwe MT, Yit NL, Quek SZ, Pang EP, Looi WS, Nei WL, Wang ML, Chua ML, Tan TW, Chua ET, Ng CT, Tuan JK. Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study. Cardiooncology. 2022 Mar 14;8(1):4. https://doi.org/10.1186/s40959-022-00131-4 

Ng WT, Chua ML, Lee AW. Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis? J Clin Oncol. 2022 Feb 25:JCO2200099. https://doi.org/10.1200/jco.22.00099 

Chiong E, Murphy DG, Buchan NC, Chua ML, et al. Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements. Asia Pac J Clin Oncol. 2022 Feb 8. https://doi.org/10.1111/ajco.13722 

Han S, Zhuang Q, Chiang J, Tan SH, Chua GW, Xie C, Chua ML, Soon YY, Yang VS. Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. BMJ Open. 2022 Feb 7;12(2):e044661. https://doi.org/10.1136/bmjopen-2020-044661 

Tang SQ, Chen L, Li WF, Chan ATC, Huang SH, Chua ML, O'Sullivan B, Lee AWM, Lee NY, Zhang Y, Chen YP, Xu C, Sun Y, Tang LL, Ma J. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiother Oncol. 2022 Feb;167:179-186. https://doi.org/10.1016/j.radonc.2021.12.029 

Lee LS, Sim AY, Ong CW, Yang X, Ng CC, Liu W, Rajasegaran V, Lim AM, Aslim EJ, Ngo NT, Khor LY, Kanesvaran R, Allen JC, Tay KJ, Yuen JS, Chong TW, Ho SS, Teh BT, Chua ML. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022 Jan 28. https://doi.org/10.1038/s41391-022-00496-8 

Ng WT, Choi H, Chua ML, Lee AW. In Reply to Abbasi et al. Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):262-263. https://doi.org/10.1016/j.ijrobp.2021.09.019  

Tan LL, Le QT, Lee NY, Chua ML. JUPITER-02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps. Cancer Commun (Lond). 2022 Jan;42(1):56-59. https://doi.org/10.1002/cac2.12248

Ramotar M, Chua ML, Truong H, Hosni A, Pintilie M, Davicioni E, Fleshner NE, Dicker AP, Bristow RG, He HH, van der Kwast T, Den RB, Berlin A. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urol Oncol. 2022 Jan;40(1):5.e1-5.e13. https://doi.org/10.1016/j.urolonc.2021.08.013

Tan JS, Teh JY, Tan LL, Tan SX, Li YQ, Tan TW, Wang ML, Kanesvaran R, Ong EH, Tay KJ, Lee LS, Tuan JK, Tan DY, Chua ML. Efficacy, toxicity, and quality-of-life outcomes of ultrahypofractionated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia. Asia Pac J Clin Oncol. 2021 Dec 14. https://doi.org/10.1111/ajco.13742

Chong LM, Tng DJ, Tan LL, Chua ML, Zhang Y. Recent advances in radiation therapy and photodynamic therapy. Applied Physics Reviews. 2021 Dec 9;8(4):041322. https://doi.org/10.1063/5.0060424

Blanchard P, Lee AWM, Carmel A, Wai Tong N, Ma J, Chan ATC, Hong RL, Chen MY, Chen L, Li WF, Huang PY, Kwong DLW, Poh SSX, Ngan R, Mai HQ, Ollivier C, Fountzilas G, Zhang L, Bourhis J, Aupérin A, Lacas B, Pignon JP; MAC-NPC collaborative Group. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. Clin Transl Radiat Oncol. 2021 Nov 26;32:59-68. https://doi.org/10.1016/j.ctro.2021.11.007 

Tng DJ, Yin BC, Cao J, Ko KK, Goh KC, Chua DX, Zhang Y, Chua ML, Low JG, Ooi EE, Soo KC. Amplified parallel antigen rapid test for point-of-care salivary detection of SARS-CoV-2 with improved sensitivity. Mikrochim Acta. 2021 Dec 6;189(1):14. https://doi.org/10.1007/s00604-021-05113-4 

Lee AY, Tiwari R, Neo S, Huned D, Kumaran A, Lim CL, Chua ML, Kanesvaran R, Lee LS. The Uro-Oncology Multi-disciplinary team (MDT) Clinic–Clinical and Patient-Reported Outcomes From Implementing a New Model of Care. Proceedings of Singapore Healthcare. 2021 Nov 12:20101058211055222. https://doi.org/10.1177%2F20101058211055222

Chua KL, Chu PL, Tng DJ, Soo KC, Chua ML. Repurposing Proton Beam Therapy through Novel Insights into Tumour Radioresistance. Clin Oncol (R Coll Radiol). 2021 Nov;33(11):e469-e481. https://doi.org/10.1016/j.clon.2021.08.013

Chen FP, Lin L, Liang JH, Tan SH, Ong EH, Luo YS, Huang L, Sim AY, Wang HT, Gao TS, Deng B, Zhou GQ, Kou J, Chua ML, Sun Y. Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. Ther Adv Med Oncol. 2021 Oct 26;13:17588359211052417. https://doi.org/10.1177/17588359211052417

Li Y, Chan Kong Ngai T, Zhou S, Yap Haw Hwong J, Pang Pei Ping E, Ong Li Kuan A, Wang Lian Chek M, Chua ML, et al. A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men. Acta Oncol. 2021 Oct;60(10):1291-1295. doi: 10.1080/0284186X.2021.1950921. https://doi.org/10.1080/0284186x.2021.1950921

Emanuel O, Liu J, Schartinger VH, Nei WL, Chan YY, Tsang CM, Riechelmann H, Masterson L, Haybaeck J, Oppermann U, Willems SM, Ooft ML, Wollmann G, Howard D, Vanhaesebroeck B, Lund VJ, Royle G, Chua ML, et al. SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target. Cancers (Basel). 2021 Sep 30;13(19):4944. https://doi.org/10.3390/cancers13194944

Li H, Rong X, Hu W, Yang Y, Lei M, Wen W, Yue Z, Huang X, Chua ML, et al. Bevacizumab Combined with Corticosteroids Does Not Improve the Clinical Outcome of Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. Front Oncol. 2021 Sep 28;11:746941. https://doi.org/10.3389/fonc.2021.746941

Sin SY, Chua ML, et al. An evaluation of concordance between head and neck advanced practice radiation therapist and radiation oncologists in toxicity assessment for nasopharyngeal carcinoma patients. Tech Innov Patient Support Radiat Oncol. 2021 Sep 4;19:52-56. https://doi.org/10.1016/j.tipsro.2021.08.001

Mierzwa M, Beadle BM, Chua ML, et al. Something for Everyone From Low-Risk to High-Risk: 5 Recent Studies to Improve Treatment and Surveillance for All Patients With Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):1-8. https://doi.org/10.1016/j.ijrobp.2021.05.005 

Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, Neal DE, Giles GG, MacInnis RJ, Thibodeau SN, McDonnell SK, Cannon-Albright L, Teixeira MR, Paulo P, Cardoso M, Huff C, Li D, Yao Y, Scheet P, Permuth JB, Stanford JL, Dai JY, Ostrander EA, Cussenot O, Cancel-Tassin G, Hoegel J, Herkommer K, Schleutker J, Tammela TLJ, Rathinakannan V, Sipeky C, Wiklund F, Grönberg H, Aly M, Isaacs WB, Dickinson JL, FitzGerald LM, Chua ML, et al. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur Urol Oncol. 2021 Aug;4(4):570-579. https://doi.org/10.1016/j.euo.2020.12.001

Poon DJ, Tay LM, Ho D, Chua ML, Chow EK, Yeo EL. Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. Cancer Lett. 2021 Jul 28;511:56-67. https://doi.org/10.1016/j.canlet.2021.04.019

Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HC, Corry J, Grégoire V, Harrington KJ, Hu CS, Jensen K, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Pan JJ, Peters LJ, Poh SS, Rosenthal DI, Sanguineti G, Tao Y, Wee JT, Yom SS, Chua ML, Lee AW. International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):682-695. https://doi.org/10.1016/j.ijrobp.2021.01.041

Carsuzaa F, Lapeyre M, Gregoire V, Maingon P, Beddok A, Marcy PY, Salleron J, Coutte A, Racadot S, Pointreau Y, Graff P, Beadle B, Benezery K, Biau J, Calugaru V, Castelli J, Chua ML, et al. Recommendations for postoperative radiotherapy in head & neck squamous cell carcinoma in the presence of flaps: A GORTEC internationally-reviewed HNCIG-endorsed consensus. Radiother Oncol. 2021 Jul;160:140-147. https://doi.org/10.1016/j.radonc.2021.04.026

Chua ML, Ng WT, Lee AW. Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. Lancet Oncol. 2021 Jun;22(6):e217. https://doi.org/10.1016/s1470-2045(21)00143-1

Poh SS, Soong YL, Sommat K, Lim CM, Fong KW, Tan TW, Chua ML, et al. Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives. Cancer Commun (Lond). 2021 May;41(5):361-370. https://doi.org/10.1002/cac2.12159

Berlin A, Lovas M, Truong T, Melwani S, Liu J, Liu ZA, Badzynski A, Carpenter MB, Virtanen C, Morley L, Bhattacharyya O, Escaf M, Moody L, Goldfarb A, Brzozowski L, Cafazzo J, Chua ML, et al. Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19. JAMA Oncol. 2021 Apr 1;7(4):597-602. https://doi.org/10.1001/jamaoncol.2020.6982

Huang L, Zhang X, Bai Y, Chua KL, Xie Y, Shu X, Long B, Fan C, Lim DW, Tan SH, Wee JTS, Wang Y, Wu Y, Chua ML. Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. Oral Oncol. 2021 Apr;115:105222. https://doi.org/10.1016/j.oraloncology.2021.105222

Wu Q, Zhang H, Zhong Y, Chua ML, Xie C. Reply to Colorectal cancer and COVID-19: Do we need to raise awareness and vigilance? Cancer. 2021 Mar 15;127(6):980-981. https://doi.org/10.1002/cncr.33218

Chen YP, Ismaila N, Chua ML, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021 Mar 1;39(7):840-859. https://doi.org/10.1200/jco.20.03237

Karam SD, Anderson CM, Ma D, Chua ML, Kimple RJ. Immunotherapy in Head and Neck Cancer-Ready for Prime Time or More Research Needed? Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):647-650. https://doi.org/10.1016/j.ijrobp.2020.11.022

Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber LM, Pipinikas CP, Chung GT, Chan YY, Wu F, To KF, Tsang CM, Pearce W, Morelli D, Philpott M, Masterson L, Nibhani R, Wells G, Bell CG, Koller J, Delecluse S, Yip YL, Liu J, Forde CT, Forster MD, Jay A, Dudás J, Krapp A, Wan S, Uprimny C, Sprung S, Haybaeck J, Fenton TR, Chester K, Thirlwell C, Royle G, Marafioti T, Gupta R, Indrasari SR, Herdini C, Slim MAM, Indrawati I, Sutton L, Fles R, Tan B, Yeong J, Jain A, Han S, Wang H, Loke KSH, He W, Xu R, Jin H, Cheng Z, Howard D, Hwang PH, Le QT, Tay JK, West RB, Tsao SW, Meyer T, Riechelmann H, Oppermann U, Delecluse HJ, Willems SM, Chua ML, et al. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun. 2021 Jan 5;12(1):117. https://doi.org/10.1038/s41467-020-20308-8

Kiljunen T, Akram S, Niemelä J, Löyttyniemi E, Seppälä J, Heikkilä J, Vuolukka K, Kääriäinen OS, Heikkilä VP, Lehtiö K, Nikkinen J, Gershkevitsh E, Borkvel A, Adamson M, Zolotuhhin D, Kolk K, Pang EPP, Tuan JKL, Master Z, Chua ML, et al. A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study. Diagnostics (Basel). 2020 Nov 17;10(11):959. https://doi.org/10.3390/diagnostics10110959 

Huang L, Sim AY, Wu Y, Liang Z, Li K, Du Y, Ong EH, Tan HQ, Wee JT, Xie Y, Shu X, Wang Y, Chua ML, Zhu X. Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol. 2020 Nov 13;12:1758835920970050. https://doi.org/10.1177/1758835920970050 

Chia BS, Leong JY, Ong AL, Lim C, Poon SH, Chua ML, Chua KL, et al. Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol. BMC Cancer. 2020 Oct 30;20(1):1045. https://doi.org/10.1186/s12885-020-07565-y 

Cai J, Zheng J, Shen J, Yuan Z, Xie M, Gao M, Tan H, Liang Z, Rong X, Li Y, Li H, Jiang J, Zhao H, Argyriou AA, Chua ML, Tang Y. A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy. Clin Cancer Res. 2020 Oct 15;26(20):5438-5447. https://doi.org/10.1158/1078-0432.ccr-20-1264 

Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020 Oct;31(10):1320-1335. https://doi.org/10.1016/j.annonc.2020.07.010 

Tan LL, Chua ML. Discovering biomarkers of radioresistance in a radiosensitive cancer: a clinical paradox in nasopharyngeal carcinoma. Ann Transl Med. 2020 Oct;8(20):1284. https://doi.org/10.21037/atm-20-5405

Huang X, Zhang X, Wang X, Rong X, Li Y, Li H, Jiang J, Cai J, Zhuo X, Pi Y, Lin J, Chua ML, et al. A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. Neurology. 2020 Sep 8;95(10):e1392-e1403. https://doi.org/10.1212/wnl.0000000000010190

You R, Liu YP, Huang PY, Zou X, Sun R, He YX, Wu YS, Shen GP, Zhang HD, Duan CY, Tan SH, Cao JY, Li JB, Xie YL, Zhang YN, Wang ZQ, Yang Q, Lin M, Jiang R, Zhang MX, Hua YJ, Tang LQ, Zhuang AH, Chen QY, Guo L, Mo HY, Chen Y, Mai HQ, Ling L, Liu Q, Chua ML, Chen MY. Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 1;6(9):1345-1352. https://doi.org/10.1001/jamaoncol.2020.1808 

Chua ML, Yu J, Xie C. Risk of COVID-19 in Patients With Cancer-Reply. JAMA Oncol. 2020 Sep 1;6(9):1472-1473. https://doi.org/10.1001/jamaoncol.2020.2589 

Xie C, Wang X, Liu H, Bao Z, Yu J, Zhong Y, Chua ML. Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China. JAMA Oncol. 2020 Sep 1;6(9):1457-1459. https://doi.org/10.1001/jamaoncol.2020.2783

Chua KL, Fehlings M, Yeo EL, Nardin A, Sumatoh H, Chu PL, Nei WL, Ong EH, Woo WY, Low KP, Wang H, Poon DJ, Liang ZG, Yao K, Huang L, Toh CK, Ang MK, Farid M, Cheng XM, Kanesvaran R, Dent R, Wee JT, Lim TK, Iyer NG, Tan DS, Soo KC, Newell EW, Chua ML. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):70-80. https://doi.org/10.1016/j.ijrobp.2020.06.007

Zhang H, Wang L, Chen Y, Wu Q, Chen G, Shen X, Wang Q, Yan Y, Yu Y, Zhong Y, Wang X, Chua ML, Xie C. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer. 2020 Sep 1;126(17):4023-4031. https://doi.org/10.1002/cncr.33042 

Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua ML, et al. Evolution of Cancer Care in Response to the COVID-19 Pandemic. Oncologist. 2020 Sep;25(9):e1426-e1427. https://doi.org/10.1634/theoncologist.2020-0451 

Wu Q, Chu Q, Zhang H, Yang B, He X, Zhong Y, Yuan X, Chua ML, Xie C. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. Cancer Commun (Lond). 2020 Aug;40(8):374-379. https://doi.org/10.1002/cac2.12077

Tan HQ, Koh WY, Yeo EL, Ang KW, Poon DJ, Lim CP, Vajandar SK, Chen CB, Ren M, Osipowicz T, Soo KC, Chua ML, Park SY. Dosimetric uncertainties impact on cell survival curve with low energy proton. Phys Med. 2020 Aug;76:277-284. https://doi.org/10.1016/j.ejmp.2020.07.005

Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua ML, et al. In Reply. The Oncologist. 2020 Aug;25(8):e1252-e1253. https://doi.org/10.1634/theoncologist.2020-0329

Miao J, Di M, Chen B, Wang L, Cao Y, Xiao W, Wong KH, Huang L, Zhu M, Huang H, Huang S, Han F, Deng X, Xiang Y, Lv X, Xia W, Tan SH, Wee JT, Guo X, Chua ML, Zhao C. A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):672-682. https://doi.org/10.1016/j.ijrobp.2020.03.029

Yu J, Ouyang W, Chua ML, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020 Jul 1;6(7):1108-1110. https://doi.org/10.1001/jamaoncol.2020.0980

Pang EP, Knight K, Park SY, Lian W, Master Z, Baird M, Chan JW, Wang ML, Tan TW, Chua ML, Chua ET, Looi WS, Nei WL, Tuan JK. Duration-dependent margins for prostate radiotherapy-a practical motion mitigation strategy. Strahlenther Onkol. 2020 Jul;196(7):657-663. https://doi.org/10.1007/s00066-019-01558-y

Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua ML, et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. Oncologist. 2020 Jun;25(6):e936-e945. https://doi.org/10.1634/theoncologist.2020-0213

Chua ML, et al. Follow-Up and Management of Patients With Head and Neck Cancer During the 2019 Novel Coronavirus (SARS-CoV-2) Disease Pandemic. Adv Radiat Oncol. 2020 May 15;5(4):631-636. https://doi.org/10.1016/j.adro.2020.04.031

Masterson L, Howard J, Gonzalez-Cruz J, Jackson C, Barnett C, Overton L, Liu H, Ladwa R, Simpson F, McGrath M, Wallwork B, Jones T, Ottensmeier C, Chua ML, et al. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation? Int J Cancer. 2020 Apr 15;146(8):2305-2314. https://doi.org/10.1002/ijc.32869

Glicksman RM, Tjong MC, Neves-Junior WF, Spratt DE, Chua KL, Mansouri A, Chua ML, et al. Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review. JAMA Oncol. 2020 Apr 1;6(4):567-577. https://doi.org/10.1001/jamaoncol.2019.5351

Margalit DN, Karam SD, Chua ML, et al. Four Influential Clinical Trials in Human Papilloma Virus-Associated Oropharynx Cancer. Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):893-899. https://doi.org/10.1016/j.ijrobp.2019.12.015

Guo YM, Chen JR, Feng YC, Chua ML, Zeng Y, Hui EP, Chan AK, Tang LQ, Wang L, Cui Q, Han HQ, Luo CL, Lin GW, Liang Y, Liu Y, He ZL, Liu YX, Wei PP, Liu CJ, Peng W, Han BW, Zuo XY, Ong EH, Yeo EL, Low KP, et al. Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exome-Wide Association Study in Multiple Cohorts. Adv Sci (Weinh). 2020 Mar 20;7(10):1903727. https://doi.org/10.1002/advs.201903727

Huang L, Chua ML. Surgery as an alternative to radiotherapy in early-stage nasopharyngeal carcinoma: innovation at the expense of uncertainty. Cancer Commun (Lond). 2020 Mar;40(2-3):119-121. https://doi.org/10.1002/cac2.12015

Chan J, Yap SY, Fong YC, Lim HC, Toh CK, Ng QS, Rajasekaran T, Chua ML, et al. Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience. Asia Pac J Clin Oncol. 2020 Feb;16(1):75-79. https://doi.org/10.1111/ajco.13241

Hou W, Chen Q, Wang H, Qiu P, Lyu X, Chen W, Chua ML, et al. The metabolic footprint during adipocyte commitment highlights ceramide modulation as an adequate approach for obesity treatment. EBioMedicine. 2020 Jan;51:102605. https://doi.org/10.1016/j.ebiom.2019.102605

Rangabashyam M, Wee HE, Wang W, Mueller S, Karim KA, Skanthakumar T, Hariraman B, Sommat K, Soong YL, Chua ML, et al. Electronic tumor board presentations as the basis for the development of a head and neck cancer database. Laryngoscope Investig Otolaryngol. 2020 Jan 19;5(1):46-54. https://doi.org/10.1002/lio2.337

Zhang Z, Jayakumar MK, Zheng X, Shikha S, Zhang Y, Bansal A, Poon DJ, Chu PL, Yeo EL, Chua ML, et al. Upconversion superballs for programmable photoactivation of therapeutics. Nat Commun. 2019 Oct 8;10(1):4586. https://doi.org/10.1038/s41467-019-12506-w

Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi TN, Rouette A, Foucal A, Espiritu SMG, Sinha A, Sam M, Timms L, Johns J, Wong A, Murison A, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Lupien M, Fradet Y, Têtu B, McPherson JD, Pasaniuc B, Kislinger T, Chua ML, et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat Med. 2019 Oct;25(10):1615-1626. https://doi.org/10.1038/s41591-019-0579-z

Liu LT, Chua ML, et al. Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun (Lond). 2019 Oct 25;39(1):64. https://doi.org/10.1186/s40880-019-0398-0

Liang ZG, Tan HQ, Zhang F, Rui Tan LK, Lin L, Lenkowicz J, Wang H, Ong EH, Kusumawidjaja G, Phua JH, Gan SA, Sin SY, Ng YY, Tan TW, Soong YL, Fong KW, Park SY, Soo KC, Wee JT, Zhu XD, Valentini V, Boldrini L, Sun Y, Chua ML. Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma. Br J Radiol. 2019 Oct;92(1102):20190271. https://doi.org/10.1259/bjr.20190271

Chua ML, Sun Y, Supiot S. Advances in nasopharyngeal carcinoma-"West meets East". Br J Radiol. 2019 Oct;92(1102):20199004. https://doi.org/10.1259/bjr.20199004

Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua ML, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. https://doi.org/10.1056/nejmoa1905287

Lv J, Chen Y, Zhou G, Qi Z, Tan KR, Wang H, Lin L, Chen F, Zhang L, Huang X, Liu R, Xu S, Chen Y, Ma J, Chua ML, Sun Y. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019 Sep 2;10(1):3941. https://doi.org/10.1038/s41467-019-11853-y

Chu PL, Shihabuddeen WA, Low KP, Poon DJ, Ramaswamy B, Liang ZG, Nei WL, Chua KL, Thong PS, Soo KC, Yeo EL, Chua ML. Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment. Photodiagnosis Photodyn Ther. 2019 Sep;27:367-374. https://doi.org/10.1016/j.pdpdt.2019.06.008

Tan MT, Wee JT, Chua ML. The Hunt for the Perfect Biomarker in Nasopharyngeal Carcinoma-the RRAS" race" beyond Epstein-Barr virus?. Translational Cancer Research. 2019 Sep; 8(5): 1659-1662 https://doi.org/10.21037/tcr.2019.08.02

Anderson CM, Kimple RJ, Lin A, Karam SD, Margalit DN, Chua ML. De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse? Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):705-709. https://doi.org/10.1016/j.ijrobp.2019.02.054

Lin L, Dou Q, Jin YM, Zhou GQ, Tang YQ, Chen WL, Su BA, Liu F, Tao CJ, Jiang N, Li JY, Tang LL, Xie CM, Huang SM, Ma J, Heng PA, Wee JT, Chua ML, et al. Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. Radiology. 2019 Jun;291(3):677-686. https://doi.org/10.1148/radiol.2019182012

Chua ML. Circulating Tumor DNA to Personalize Treatment in Nasopharynx Cancer - Time to Look "Ahead"? Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):362-364. https://doi.org/10.1016/j.ijrobp.2019.02.043

Bin Lim S, Chua ML, et al. Pan-cancer analysis connects tumor matrisome to immune response. NPJ Precis Oncol. 2019 May 22;3:15. https://doi.org/10.1038/s41698-019-0087-0

Iyer NG, Chua ML. Multidisciplinary team meetings - challenges of implementation science. Nat Rev Clin Oncol. 2019 Apr;16(4):205-206. https://doi.org/10.1038/s41571-018-0148-2

Zhao C, Miao J, Shen G, Li J, Shi M, Zhang N, Hu G, Chen X, Hu X, Wu S, Chen J, Shao X, Wang L, Han F, Mai H, Chua ML, Xie C. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. Ann Oncol. 2019 Apr 1;30(4):637-643. https://doi.org/10.1093/annonc/mdz020

Chua ML, Chua KL, Wee JT. Coming of age of bevacizumab in the management of radiation-induced cerebral necrosis. Ann Transl Med. 2019 Apr;7(7):155. https://doi.org/10.21037/atm.2019.03.17

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua ML, et al. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 2019 Feb 7;176(4):831-843.e22. https://doi.org/10.1016/j.cell.2019.01.025

Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, Yao CQ, Sabelnykova VY, Fraser M, Chua ML, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat Genet. 2019 Feb;51(2):308-318. https://doi.org/10.1038/s41588-018-0318-2

Chua ML. Editorial comment on Berlin et al. International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy. Journal of Urology 2019 Feb; 201(2):291. https://doi.org/10.1097/01.JU.0000552990.38155.41

Tan JS, Goh CXY, Koh YS, Li Y, Tuan JK, Chua ET, Tan TW, Wang ML, Lee LS, Tay KJ, Kanesvaran R, Toh CK, Tong AK, Lam WW, Chua ML. 68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biol Med. 2019 Feb;16(1):157-166. https://doi.org/10.20892/j.issn.2095-3941.2018.0288

Chen YP, Wang YQ, Lv JW, Li YQ, Chua ML, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Ann Oncol. 2019 Jan 1;30(1):68-75. https://doi.org/10.1093/annonc/mdy470

Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, Chua ML. Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):84-91. https://doi.org/10.1016/j.ijrobp.2018.08.030

Chua KL, Yeo EL, Shihabudeen WA, Tan SH, Shwe TT, Ong EH, Lam PY, Soo KC, Soong YL, Fong KW, Tan TW, Wee JT, Chua ML. Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC. BMC Cancer. 2018 Nov 12;18(1):1095. https://doi.org/10.1186/s12885-018-5005-2

Liang ZG, Kusumawidjaja G, Kazmi F, Wee JT, Chua ML. Intensity-modulated radiotherapy for paranasal sinuses and base of skull tumors. Oral Oncol. 2018 Nov;86:61-68. https://doi.org/10.1016/j.oraloncology.2018.09.010

Liu X, Zhang Y, Tang LL, Le QT, Chua ML, et al. Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncol. 2018 Aug 1;4(8):1073-1079. https://doi.org/10.1001/jamaoncol.2018.0887

Bissey PA, Law JH, Bruce JP, Shi W, Renoult A, Chua ML, et al. Dysregulation of the MiR-449b target TGFBI alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma. Oncogenesis. 2018 May 22;7(5):40. https://doi.org/10.1038/s41389-018-0050-x

Espiritu SM, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, Fox NS, Chua ML, et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell. 2018 May 3;173(4):1003-1013.e15. https://doi.org/10.1016/j.cell.2018.03.029

Li YQ, Tan JS, Wee JT, Chua ML. Adaptive radiotherapy for head and neck cancers: Fact or fallacy to improve therapeutic ratio? Cancer Radiother. 2018 May;22(3):287-295. https://doi.org/10.1016/j.canrad.2018.01.003

Poh SS, Chua ML, Wee JT. Why we should give spatially fractionated radiation therapy (GRID) a second look—especially in nasopharyngeal carcinoma. Annals of Nasopharynx Cancer. 2018;2(4):12-9. http://dx.doi.org/10.21037/anpc.2018.04.01 

Yeo EL, Li YQ, Soo KC, Wee JS, Chua ML. Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma. Chin Clin Oncol. 2018 Apr;7(2):15. https://doi.org/10.21037/cco.2018.04.05

Li YQ, Tian YM, Tan SH, Liu MZ, Kusumawidjaja G, Ong EH, Zhao C, Tan TW, Fong KW, Sommat K, Soong YL, Wee JT, Han F, Chua ML. Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. J Clin Oncol. 2018 Mar 20;36(9):891-899. https://doi.org/10.1200/jco.2017.75.5165

Berlin A, Ahmad AE, Chua ML, et al. Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):702-709. https://doi.org/10.1016/j.ijrobp.2017.10.041

Li YQ, Khin NS, Chua ML. The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma. Cancer Biol Med. 2018 Feb;15(1):1-5. https://doi.org/10.20892/j.issn.2095-3941.2017.0176

Li YQ, Chua ET, Chua KL, Chua ML. "Cor Occidere": a novel strategy of targeting the tumor core by radiosurgery in a radio- and chemo-resistant intracranial hemangiopericytoma. Chin Clin Oncol. 2018 Feb;7(1):10. https://doi.org/10.21037/cco.2018.01.02

Guan SP, Lam AT, Newman JP, Chua KL, Kok CYL, Chong ST, Chua ML, Lam PYP. Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex. FEBS Open Bio. 2017 Nov 23;8(1):15-26. https://doi.org/10.1002/2211-5463.12330

Miller JA, Guillozet-Bongaarts A, Gibbons LE, Postupna N, Renz A, Beller AE, Sunkin SM, Ng L, Rose SE, Smith KA, Szafer A, Barber C, Bertagnolli D, Bickley K, Brouner K, Caldejon S, Chapin M, Chua ML, et al. Neuropathological and transcriptomic characteristics of the aged brain. Elife. 2017 Nov 9;6:e31126. https://doi.org/10.7554/elife.31126

Chua ML, et al. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. Eur Urol. 2017 Nov;72(5):665-674. https://doi.org/10.1016/j.eururo.2017.04.034

Chua ML, et al. Intraductal Carcinoma of the Prostate: Anonymous to Ominous. Eur Urol. 2017 Oct;72(4):496-498. https://doi.org/10.1016/j.eururo.2017.04.004

Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua ML, et al. Mitochondrial mutations drive prostate cancer aggression. Nat Commun. 2017 Sep 22;8(1):656. https://doi.org/10.1038/s41467-017-00377-y

Tan JS, Lin X, Chua KL, Lam PY, Soo KC, Chua ML. Exploiting molecular genomics in precision radiation oncology: a marriage of biological and physical precision. Chin Clin Oncol. 2017 Sep;6(Suppl 2):S19. https://doi.org/10.21037/cco.2017.06.31  

Chua KL, Sin I, Fong KW, Chua ML, Onishi H. Stereotactic body radiotherapy for early stage lung cancer-historical developments and future strategies. Chin Clin Oncol. 2017 Sep;6(Suppl 2):S20. https://doi.org/10.21037/cco.2017.08.02 

Chua KL, Tan DB, Chua ML, Lo SS. The promise of stereotactic body radiotherapy-next phase of integration into oncological practice. Chin Clin Oncol. 2017 Sep;6(Suppl 2):S8. https://doi.org/10.21037/cco.2017.08.03

Lalonde E, Alkallas R, Chua ML, et al. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. Eur Urol. 2017 Jul;72(1):22-31. https://doi.org/10.1016/j.eururo.2016.10.013

Mahamud O, So J, Chua ML, Bristow RG. Targeting DNA repair for precision radiotherapy: Balancing the therapeutic ratio. Curr Probl Cancer. 2017 Jul-Aug;41(4):265-272. https://doi.org/10.1016/j.currproblcancer.2017.04.002

Raziee H, Moraes FY, Murgic J, Chua ML, et al. Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiother Oncol. 2017 Jun;123(3):459-465. https://doi.org/10.1016/j.radonc.2017.04.003

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017 Jan 19;541(7637):359-364. http://doi.org/10.1038/nature20788

Chua KL, Kusumawidjaja G, Murgic J, Chua ML. Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy? ESMO Open. 2017 Mar 7;1(6):e000123. https://doi.org/10.1136/esmoopen-2016-000123

Chua ML, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. Eur J Cancer. 2016 Nov;67:119-129. https://doi.org/10.1016/j.ejca.2016.08.006

Chua ML, Chan AT. Gemcitabine: a game changer in nasopharyngeal carcinoma. Lancet. 2016 Oct 15;388(10054):1853-1854. https://doi.org/10.1016/s0140-6736(16)31394-0

Chua ML, Bristow RG. Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy? Clin Cancer Res. 2016 Jul 1;22(13):3124-6. https://doi.org/10.1158/1078-0432.ccr-16-0381

Nuta O, Somaiah N, Boyle S, Chua ML, et al. Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy. Cancer Lett. 2016 May 1;374(2):324-30. https://doi.org/10.1016/j.canlet.2016.02.036

Somaiah N, Chua ML, et al. Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy. Radiother Oncol. 2016 May;119(2):244-9. https://doi.org/10.1016/j.radonc.2016.04.012

Wee JT, Soong YL, Poh SS, Chua ML. Nasopharyngeal carcinoma-some closing remarks. Chin Clin Oncol. 2016 Apr;5(2):29. https://doi.org/10.21037/cco.2016.03.23

Wee JT, Soong YL, Chua ML. Nasopharyngeal carcinoma-past lessons and a glimpse into the future. Chin Clin Oncol. 2016 Apr;5(2):14. https://doi.org/10.21037/cco.2016.04.03

Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet. 2016 Mar 5;387(10022):1012-1024. https://doi.org/10.1016/s0140-6736(15)00055-0

Kusumawidjaja G, Gan PZ, Ong WS, Teyateeti A, Dankulchai P, Tan DY, Chua ET, Chua KL, Tham CK, Wong FY, Chua ML. Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme. Onco Targets Ther. 2016 Mar 2;9:1115-22. https://doi.org/10.2147/OTT.S96509

Poh SS, Chua ML, Wee JT. Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. Chin J Cancer. 2016 Jan 6;35:9. https://doi.org/10.1186/s40880-015-0068-9

Chua ML, et al. DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. Radiat Environ Biophys. 2014 May;53(2):355-64. https://doi.org/10.1007/s00411-014-0531-z

Chua ML, Rothkamm K. Biomarkers of radiation exposure: can they predict normal tissue radiosensitivity? Clin Oncol (R Coll Radiol). 2013 Oct;25(10):610-6. https://doi.org/10.1016/j.clon.2013.06.010

Lim TC, Chua ML, et al. Comparison of MRI, CT and 18F-FDG-PET/CT for the detection of intracranial disease extension in nasopharyngeal carcinoma. Head & Neck Oncology. 2012 Sept 9;4(2):49.

Chua ML, et al. In vitro interaction of cyclooxygenase-2 inhibitors with radiation in nasopharyngeal carcinoma cell line: Dependence on sequence of administration. Austral-Asian Journal of Cancer. 2012 Jan;11(1):27-31.

Chua ML, et al. Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Radiother Oncol. 2011 Jun;99(3):362-6. https://doi.org/10.1016/j.radonc.2011.05.071

Chua ML, et al. Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. Radiother Oncol. 2011 May;99(2):225-30. https://doi.org/10.1016/j.radonc.2011.04.009

Loong SL, Hwang JS, Li HH, Wee JT, Yap SP, Chua ML, et al. Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). Radiat Oncol. 2009 Jul 10;4:23. https://doi.org/10.1186/1748-717X-4-23

Chua ML, et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma. Head Neck. 2009 Mar;31(3):346-54. https://doi.org/10.1002/hed.20974